Search
Sulbactam
go.drugbank.com/drugs/DB09324ApprovedInvestigational[L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]
Atomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigationalLong-acting formulations of psychostimulants (such as [DB00422], [DB01576], and [DB01255]) are typically considered the most effective and first-line treatment for ADHD in adults and children as recommended … is a limiting factor associated with the use of stimulant medications such as [DB00422], [DB01576], and [DB01255].
anti-alpha5Beta1-integrin antibody
go.drugbank.com/drugs/DB05870Experimentalwell as other pro-angiogenic growth factors. … during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), as
Penicillamine
go.drugbank.com/drugs/DB00859ApprovedInvestigationalThe pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine).
Thrombomodulin Alfa
go.drugbank.com/drugs/DB05777ApprovedIt is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular
Lanolin alcohols
go.drugbank.com/drugs/DB14181ApprovedIt is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing.
Perospirone
go.drugbank.com/drugs/DB08922InvestigationalDainippon Sumitomo Pharma developed perospirone in Japan in 2001 for the treatment of acute schizophrenia and bipolar mania as well as chronic schizophrenia. … It is commonly present as the hydrated hydrochloride salt form.
GTI 2040
go.drugbank.com/drugs/DB05801InvestigationalGTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Solifenacin
go.drugbank.com/drugs/DB01591ApprovedInvestigational[L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511]